Laboratory Services News & Publications

Laboratory Services News

Effective Monday, December 6, 2021, Nationwide Children's Laboratory Services will change notification of Laboratory Courtesy results to community physicians. For more information, please click here.

 

Testing Updates

On May 16, 2022, Group A Strep rRNA GenProb  (test code GASDRP) will be retired and replaced with Group A Strep, Molecular (test code GASM). The new GASM test will require the same COPAN/BBL dual/single culture swab in liquid Stuart’s transport media. Only throat swabs are acceptable. For more information, click here.

 

On March, 14, 2022, the Institute for Genomic Medicine (IGM) Clinical Laboratory will be offering a new test called Next Generation Sequencing (NGS) Neuroblastoma Panel. Please note, this test will be replacing the ALK Targeted Sequencing Assay (test code ALK). For more information, click here.

 

On March 7, 2022, the NCH Institute for Genomic Medicine (IGM) Clinical Laboratory will start offering a new test called Spinal Muscular Atrophy (SMA) Dosage Analysis. Please note, this test will be replacing the ALK Targeted Sequencing Assay (test code ALK). For more information, click here.

 

On February 23, 2022, Quantitative Amino Acid testing for CSF (QAAC), Serum/Plasma (QAAS),Urine (QAAUP), and Maple Syrup Disease Monitor (MSUD) will be updated to a new methodology of Liquid Chromatography – Tandem Mass Spectrometry (LC-MS/MS) from High Performance Liquid Chromatography (HPLC). A cross reference of old to new test codes are shown below:

 

 

 

 

New Reference Ranges

December 6, 2022

HVA and VMA Reference Ranges

 

June 27. 2022

CSF Cell Count Reference Ranges

 

May 16, 2022

Lead Testing-Whole Blood and Filter Card

 

February 23, 2022:

Plasma Amino Acids

Urine Amino Acids

CSF Amino Acids

Osmolality Serum and Plasma

 

 

Sexually Transmitted Infection Testing Resources

Nationwide Children’s Laboratory Services provides resources for health care professionals, including a Sexually Transmitted Infections Practice Tool. Visit Clinical Tools for a complete list.

Included in the current STI Practice Tool are recommendations from the Centers for Disease Control and Prevention (CDC) regarding “opt-out” testing policies.

According to CDC recommendations, providers might consider opt-out chlamydia and gonorrhea screening (i.e., the patient is notified that testing will be performed unless the patient declines, regardless of reported sexual activity) for adolescent and young adult females during clinical encounters. Cost-effectiveness analyses indicate that opt-out chlamydia screening among adolescent and young adult females might substantially increase screening, be cost saving and identify infections among patients who do not disclose sexual behavior.

Nationwide Children’s has provided sample opt-out letters that providers may download and customize for patient/parent communication:

Patient Letter (Customizable)

Download:

Parent Letter (Customizable)

Download: